Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
9 articles
Newest firstIntroduction The use of medical cannabis products is expanding, yet real-world data on associated adverse events (AEs) remain limited. Controlled trials often exclude diverse patient populations and product types, making post-marketing surveillance essential to understanding cannabinoid safety. Objective The aim of this study is to characterize AEs reported by patients enrolled in the Minnesota Medical Cannabis Pr…
Open article record in new tab ↗Background The applicability of spontaneous reporting systems such as the US Food and Drug Administration Adverse Event Reporting System (FAERS) to detect cannabis-related safety signals remains unclear due to the potential for discrepant reporting patterns between pharmaceutical and non-pharmaceutical cannabis-derived products (CDPs). Methods We conducted a descriptive analysis of seven groups of CDP reports subm…
Open article record in new tab ↗Background Seizures after the use of cannabinoids are reported, but no precise descriptions of the characteristics of subjects and factors that may trigger seizures are available. Objectives To study the characteristics and circumstances associated with the occurrence of seizures in individuals using cannabinoids for medical or recreational purposes. Methods A retrospective analysis of spontaneous reports of adver…
Introduction This study aimed to evaluate the utilization of medical cannabis in a pediatric population and compare short-term persistence rates with those in adolescents and young adults. Methods In this retrospective, nationwide cohort study supplemented by data from an open-label study of children with ASD, patient cases under 12 years of age who received medical cannabis treatment between 2018 and 2022 were an…
Open article record in new tab ↗IntroductionMedical cannabis use has expanded rapidly, yet long-term real-world safety data remain limited. We evaluated adverse-event (AE) frequency, severity, and predictors in a US telehealth registry of medical cannabis patients over one year. MethodsWe analyzed 14,313 adults who completed intake between June-August 2024. Patients reported any of 30 prespecified adverse events (AEs) and rated each on a 0-10 im…
Open article record in new tab ↗Background Cannabis and its derivatives show encouraging therapeutic effects in the treatment of various diseases. However, further studies are needed to better assess their efficacy and safety. A promising base for research in the field of medicine and additional pharmacovigilance is social networks, in which experience and knowledge are exchanged between researchers, doctors, and patients, as well as information…
Open article record in new tab ↗AimsTo correlate potential links between the suspected adverse drug reaction (ADR) profile of licensed non-steroidal androgen receptor antagonists (NSARA) with their unique chemical properties and known off-target polypharmacology. MethodsPhysiochemical and polypharmacology data was curated from the Electronic Medicines Compendium, FDA New Drug Applications documents, and ChEMBL databases. System organ class (SOC,…
Open article record in new tab ↗Introduction: Cannabidiol (CBD) is an active chemical contained in the plant Cannabis sativa. It is a resorcinol-based compound that crosses the blood-brain barrier without causing euphoric effects. CBD has a plethora of pharmacological effects of therapeutic interest. CBD has been authorized in the European Union as an anticonvulsant against serious infantile epileptic syndromes, but its safety profile is still n…
Open article record in new tab ↗Introduction Medications which target benzodiazepine (BZD) binding sites of GABAA receptors (GABAARs) have been in widespread use since the nineteen-sixties. They carry labels as anxiolytics, hypnotics or antiepileptics. All benzodiazepines and several nonbenzodiazepine Z-drugs share high affinity binding sites on certain subtypes of GABAA receptors, from which they can be displaced by the clinically used antagoni…